At a time when investors are questioning the sustainability of pharmaceutical business models, reliable execution has become ...

Modern PBMs, or PBM-like functions, should operate with full line-of-sight to net price and patient outcomes. Full ...

One of which revolved around “Optimizing GTN Strategy—Balancing Channel Economics and Market Access,” led by Lannett ...

Although he typically revises his macro framework only once every decade or more, Roth explained that the current environment ...

In today’s Pharma Pulse, the FDA approves Amgen’s Uplizna (inebilizumab-cdon), the first CD19-targeted therapy for gMG with convenient twice-yearly dosing, and much more.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, ...

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, hopes to use the conference to explore how ...

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, discusses how the convergence of patient access ...

Point-of-care engagement is essential for converting investments in payer negotiations and copay programs into prescriptions.

The 20th installment of Trade & Channel Strategies carried on with a focus on boosting access to medication.

In today’s Pharma Pulse, Augmentin XR is the first drug approved under the FDA's new CNPV pilot program and much more.